GO:0150159 negative regulation of interleukin-34 production: Cytokine Control Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0150159 describes the biological process that reduces or stops the production of interleukin-34 (IL-34), a cytokine that binds CSF1R and supports myeloid cell survival and function.
• IL-34 is secreted by many cell types and is elevated in several cancers, where it can promote tumor-associated macrophage recruitment and poor prognosis.
• Negative regulation of IL-34 production is relevant to cancer biology, inflammation, and immune homeostasis, and it is studied using CRISPR knockout, point mutation, knock-in, and overexpression models.
• Key genes and pathways that can influence IL-34 production include CSF1R, NF-kB, STAT3, and other cytokine-regulatory factors, though direct evidence for many candidates remains limited.
• Researchers use RNA-seq, proteomics, ELISA, and CRISPR screening to identify regulators of IL-34 production and to validate their effects.
• EDITGENE provides CRISPR cell model services to study negative regulation of IL-34 production, including knockout, point mutation, knock-in, overexpression, and library screening.
Description
Interleukin-34 (IL-34) is a cytokine that binds to CSF1R and regulates the survival, proliferation, and differentiation of monocytes, macrophages, and other myeloid cells. Because IL-34 can shape the tumor microenvironment and is associated with poor prognosis in some cancers, understanding how its production is controlled is of significant research interest. GO:0150159, negative regulation of interleukin-34 production, captures the biological processes that reduce or prevent the synthesis and secretion of IL-34. This term is part of the Gene Ontology biological process aspect and is used to annotate gene products that downregulate IL-34 levels. Dysregulated IL-34 production has been linked to cancer progression, chronic inflammation, and autoimmune conditions. In triple-negative breast cancer, for example, IL-34 contributes to poor prognosis, suggesting that strategies to negatively regulate its production could have therapeutic potential. However, the molecular mechanisms that negatively regulate IL-34 production are not fully understood, and many candidate regulators remain to be validated. Researchers studying GO:0150159 aim to identify the genes, signaling pathways, and environmental cues that suppress IL-34 production. This article summarizes the current knowledge based on published literature, highlights key genes and experimental models, and describes how CRISPR-based tools can be used to dissect this process.
negative regulation of interleukin-34 production At A Glance
| GO ID | GO:0150159 |
|---|---|
| GO term | negative regulation of interleukin-34 production |
| Ontology | biological_process |
| Synonym | None listed |
| Major function | Reduction or prevention of interleukin-34 (IL-34) synthesis and secretion |
| Related cytokine | Interleukin-34 (IL-34), a ligand for CSF1R |
| Associated disease | Triple-negative breast cancer and other IL-34-associated pathologies |
| Research methods | CRISPR knockout, RNA-seq, proteomics, ELISA, and cytokine profiling |
What Is GO:0150159?
GO:0150159, negative regulation of interleukin-34 production, is a biological process term that describes any mechanism that decreases the rate or extent of interleukin-34 (IL-34) production. This includes transcriptional, post-transcriptional, translational, and secretory control that ultimately lowers the amount of mature IL-34 protein available for secretion. The term is used in Gene Ontology annotations to link gene products to the suppression of IL-34 synthesis or release.
Why Is negative regulation of interleukin-34 production Important in Cell Biology?
Understanding negative regulation of interleukin-34 production is important because IL-34 is a key cytokine that influences myeloid cell biology and has been implicated in cancer progression and poor prognosis. Identifying the factors that suppress IL-34 production could reveal new therapeutic targets for cancers and inflammatory diseases where IL-34 is overexpressed. Moreover, the process is likely controlled by multiple signaling pathways and transcription factors, making it a rich area for functional genomics and CRISPR screening.
• IL-34 is elevated in triple-negative breast cancer and is associated with poor prognosis.
• Negative regulation of IL-34 production may reduce tumor-associated macrophage recruitment and tumor progression.
• IL-34 modulates immune responses, so its suppression could affect inflammation and autoimmunity.
• Identifying negative regulators of IL-34 production can uncover new drug targets.
• CRISPR screens can systematically discover genes that repress IL-34 production.
• Understanding this process helps interpret cytokine networks in the tumor microenvironment.
• It provides a framework for studying post-transcriptional and secretory control of cytokines.
• It may inform biomarker development for cancers with high IL-34 levels.
• It supports the design of cell models for preclinical testing of IL-34-targeting therapies.
What Happens During negative regulation of interleukin-34 production?
Transcriptional suppression of IL-34
In simple terms: The cell reduces the reading of the IL-34 gene into messenger RNA.
Negative regulation of IL-34 production can occur at the transcriptional level, where transcription factors or chromatin modifiers bind to the IL-34 promoter and reduce its activity. This leads to lower IL-34 mRNA levels and consequently less IL-34 protein. Identifying the transcription factors involved is a key goal of functional studies.
Post-transcriptional control of IL-34 mRNA
In simple terms: The cell destroys or stabilizes the IL-34 mRNA less efficiently.
After transcription, IL-34 mRNA can be targeted by microRNAs or RNA-binding proteins that promote its degradation or inhibit its translation. Such post-transcriptional mechanisms can rapidly lower IL-34 production without affecting transcription. These pathways are often studied using RNA-seq and reporter assays.
Translational and secretory inhibition
In simple terms: The cell makes less IL-34 protein from the mRNA or releases less of it outside.
Even if IL-34 mRNA is present, its translation can be suppressed by global or specific translational control pathways. Additionally, secretory pathways may be modulated to retain IL-34 intracellularly or target it for degradation. These layers add complexity to the negative regulation of IL-34 production.
Signaling pathways that suppress IL-34
In simple terms: External signals can tell the cell to stop making IL-34.
Cytokines, growth factors, and other extracellular signals can activate intracellular cascades that ultimately inhibit IL-34 production. For example, activation of certain STAT or NF-kB pathways may either promote or suppress IL-34 depending on context. Dissecting these context-dependent effects requires careful experimental models.
Feedback and homeostatic control
In simple terms: The cell uses feedback loops to keep IL-34 levels in check.
IL-34 itself can trigger feedback mechanisms that limit its own production, helping maintain immune homeostasis. Negative feedback loops may involve CSF1R signaling or downstream effectors. Understanding these loops is important for predicting the consequences of therapeutic IL-34 modulation.
Key Genes Involved in GO:0150159 negative regulation of interleukin-34 production
The following genes and proteins have been implicated in the regulation of IL-34 production or in related cytokine control pathways, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IL34 | Encodes interleukin-34 cytokine | Target gene whose production is negatively regulated |
| CSF1R | Receptor for IL-34 and CSF1 | Mediates IL-34 signaling and potential feedback |
| NFKB1 | Transcription factor | May regulate IL34 transcription in inflammation |
| STAT3 | Signal transducer and transcription factor | Can modulate cytokine production including IL-34 |
| STAT1 | Signal transducer and transcription factor | Potential negative regulator of cytokine production |
| JAK1 | Janus kinase | Upstream of STAT pathways affecting IL-34 |
| JAK2 | Janus kinase | Upstream of STAT pathways affecting IL-34 |
| MAPK1 | Mitogen-activated protein kinase | Signaling node that can influence cytokine secretion |
| MAPK3 | Mitogen-activated protein kinase | Signaling node that can influence cytokine secretion |
| PIK3CA | PI3K catalytic subunit | Pathway that can modulate cytokine production |
| AKT1 | Serine/threonine kinase | Downstream of PI3K, affects cytokine regulation |
| MTOR | Kinase, mTOR pathway | Central regulator of translation and cytokine production |
| EIF4E | Translation initiation factor | Controls translation of cytokine mRNAs |
| HIF1A | Hypoxia-inducible factor | Can regulate cytokine expression in tumors |
| CEBPB | Transcription factor | Regulates inflammatory gene expression |
| SPI1 | Transcription factor (PU.1) | Myeloid-specific regulator of cytokine genes |
| IRF1 | Interferon regulatory factor | Modulates cytokine transcription |
| SOCS1 | Suppressor of cytokine signaling | Negative feedback on cytokine pathways |
How Is negative regulation of interleukin-34 production Regulated?
Negative regulation of IL-34 production is likely controlled by a network of signaling pathways, including JAK-STAT, NF-kB, PI3K-AKT-mTOR, and MAPK cascades. These pathways can be activated by cytokines, growth factors, or cellular stress, leading to changes in transcription factor activity and mRNA translation. Additionally, epigenetic modifiers and microRNAs may contribute to the suppression of IL-34 production. The precise mechanisms are context-dependent and require further experimental validation.
negative regulation of interleukin-34 production and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IL34 | Triple-negative breast cancer | IL34 knockout breast cancer cell lines |
| CSF1R | Cancer and inflammation | CSF1R point mutation knock-in models |
| NFKB1 | Inflammatory diseases | NFKB1 knockout macrophages |
| STAT3 | Cancer and autoimmunity | STAT3 knockout or point mutation cells |
| MTOR | Cancer and metabolic disorders | MTOR knockout or overexpression models |
IL-34 in triple-negative breast cancer
IL-34 contributes to poor prognosis in triple-negative breast cancer, where it promotes an immunosuppressive tumor microenvironment. Negative regulation of IL-34 production could therefore be a therapeutic strategy to reduce tumor progression. Understanding the regulators of IL-34 in this cancer type is an active area of research.
IL-34 in inflammatory and autoimmune diseases
IL-34 is implicated in chronic inflammation and autoimmune conditions such as rheumatoid arthritis and inflammatory bowel disease. Suppressing IL-34 production may help alleviate inflammation, but the mechanisms of negative regulation are not fully defined. Targeting these pathways could offer new treatment options.
IL-34 in neurological disorders
IL-34 is expressed in the central nervous system and can influence microglial function. Dysregulated IL-34 production has been linked to neurodegenerative conditions, although the role of negative regulation is less clear. Further studies are needed to clarify these connections.
From negative regulation of interleukin-34 production-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate IL-34 production? | CRISPR knockout of gene X in IL-34-expressing cells |
| Does a specific mutation in gene Y affect IL-34 suppression? | CRISPR point mutation knock-in of the mutation |
| Does overexpression of gene Z reduce IL-34 levels? | CRISPR knock-in of a constitutive promoter or overexpression vector |
| Where is gene X expressed relative to IL-34? | Tagged knock-in with fluorescent or epitope tags |
| Which genes regulate IL-34 production in a genome-wide manner? | CRISPR library screening with IL-34 readout |
| How does IL-34 production change upon pathway activation? | Overexpression of pathway components or chemical activation |
How to Study the negative regulation of interleukin-34 production Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | IL-34 mRNA levels and transcriptome changes | Identifying transcriptional regulators |
| Proteomics | IL-34 protein abundance and secretome | Validating post-transcriptional control |
| ELISA | Secreted IL-34 protein concentration | Quantifying cytokine production |
| CRISPR screening | Genes affecting IL-34 production | Discovery of negative regulators |
| Flow cytometry | Single-cell IL-34 expression | Sorting and heterogeneity analysis |
| Immunofluorescence | Subcellular localization of IL-34 | Studying secretion and trafficking |
| Western blot | IL-34 protein levels in lysates | Confirming knockout or overexpression |
RNA-seq and transcriptomics
RNA sequencing can measure IL-34 mRNA levels and identify transcriptional changes in response to candidate negative regulators. Comparing wild-type and knockout cells reveals genes and pathways that suppress IL-34 transcription. This method is widely used in functional genomics studies.
Proteomics and cytokine profiling
Mass spectrometry-based proteomics and cytokine arrays can quantify IL-34 protein secretion and identify co-regulated proteins. These approaches complement transcriptomic data and provide insight into post-transcriptional control. ELISA is commonly used for targeted validation.
CRISPR screening
Genome-wide CRISPR knockout or activation screens can systematically identify genes that negatively regulate IL-34 production. Cells are engineered to report IL-34 levels, and sgRNA enrichment is measured after selection. This unbiased approach can uncover novel regulators.
Imaging and flow cytometry
Flow cytometry and immunofluorescence can detect intracellular and surface IL-34 in single cells. These methods allow researchers to sort populations based on IL-34 expression and study heterogeneity. Live-cell imaging can track IL-34 secretion dynamics.
How CRISPR Can Be Used to Study GO:0150159 negative regulation of interleukin-34 production
Knockout
CRISPR knockout of candidate genes can test whether they are required for negative regulation of IL-34 production. By disrupting a gene of interest and measuring IL-34 levels, researchers can determine if the gene normally suppresses IL-34. This approach is scalable for medium-throughput screens.
Point Mutation
CRISPR point mutation knock-in allows the introduction of specific amino acid changes to study their effect on IL-34 regulation. This is useful for dissecting signaling domains or phosphorylation sites in candidate regulators. It provides more precise mechanistic insight than complete knockout.
Knock-in
Knock-in of reporter genes or tags into the IL34 locus enables real-time monitoring of IL-34 production. Tagged knock-in can also facilitate protein purification and interaction studies. This approach helps track dynamic changes in IL-34 levels under different conditions.
Overexpression
CRISPR-mediated overexpression of candidate negative regulators can test whether increased dosage suppresses IL-34 production. This is achieved by knock-in of a strong promoter or by using CRISPR activation. Overexpression models are valuable for gain-of-function studies.
How EDITGENE Supports negative regulation of interleukin-34 production Research
Researchers studying negative regulation of interleukin-34 production-related genes often need to determine whether a candidate gene is causally involved in suppressing IL-34, and CRISPR-based cell models provide a robust way to establish causality. EDITGENE offers a suite of services to generate precisely engineered cell lines for such studies.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of interleukin-34 production research.
Frequently Asked Questions About negative regulation of interleukin-34 production
What is GO:0150159?
GO:0150159 is the Gene Ontology term for negative regulation of interleukin-34 production, describing processes that reduce or prevent the synthesis and secretion of IL-34.
What is interleukin-34?
Interleukin-34 (IL-34) is a cytokine that binds CSF1R and regulates myeloid cell survival and function, and it is implicated in cancer and inflammation.
What genes are involved in negative regulation of interleukin-34 production?
Genes such as CSF1R, NFKB1, STAT3, and other signaling components have been implicated, though direct evidence for many candidates is still emerging.
How is IL-34 production negatively regulated?
It can be controlled at transcriptional, post-transcriptional, translational, and secretory levels by various signaling pathways and factors.
Why is negative regulation of IL-34 production important in cancer?
IL-34 is associated with poor prognosis in triple-negative breast cancer, so suppressing its production may reduce tumor progression.
What experimental models are used to study IL-34 regulation?
CRISPR knockout, point mutation, knock-in, overexpression cell lines, and CRISPR screens are commonly used.
How can CRISPR screening help identify regulators of IL-34?
Genome-wide CRISPR screens can systematically knock out or activate genes and measure IL-34 levels to find negative regulators.
What diseases are linked to IL-34?
IL-34 has been linked to triple-negative breast cancer, inflammatory diseases, and neurological disorders.
Can IL-34 production be targeted therapeutically?
Modulating IL-34 production is a potential therapeutic strategy, but more research is needed to identify safe and effective targets.
What services does EDITGENE offer for IL-34 research?
EDITGENE provides CRISPR knockout, point mutation, knock-in, overexpression, library screening, and bioinformatics services.
Conclusion
GO:0150159, negative regulation of interleukin-34 production, is a critical biological process that controls the levels of a cytokine involved in cancer, inflammation, and immune regulation. Although the precise molecular mechanisms are still being elucidated, CRISPR-based functional genomics offers powerful tools to identify and validate the genes that suppress IL-34. Continued research in this area may lead to new therapeutic strategies for diseases characterized by aberrant IL-34 production.
References
- 1. Kajihara N et al.. 2020. Interleukin-34 contributes to poor prognosis in triple-negative breast cancer.. Breast Cancer 27(6):1198-1204 PMID: 32578004
